Predicting atrial fibrillation after cryptogenic stroke via a clinical risk score-a prospective observational study.


Journal

European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311

Informations de publication

Date de publication:
01 2022
Historique:
received: 07 09 2021
accepted: 09 09 2021
pubmed: 15 9 2021
medline: 5 4 2022
entrez: 14 9 2021
Statut: ppublish

Résumé

Atrial fibrillation (AF) often remains undiagnosed in cryptogenic stroke (CS), mostly because of limited availability of cardiac long-term rhythm monitoring. There is an unmet need for a pre-selection of CS patients benefitting from such work-up. A clinical risk score was therefore developed for the prediction of AF after CS and its performance was evaluated over 1 year of follow-up. Our proposed risk score ranges from 0 to 16 points and comprises variables known to be associated with occult AF in CS patients including age, N-terminal pro-brain natriuretic peptide, electrocardiographic and echocardiographic features (supraventricular premature beats, atrial runs, atrial enlargement, left ventricular ejection fraction) and brain imaging markers (multi-territory/prior cortical infarction). All CS patients admitted to our Stroke Unit between March 2018 and August 2019 were prospectively followed for AF detection over 1 year after discharge. During the 1-year follow-up, 24 (16%) out of 150 CS patients with AF (detected via electrocardiogram controls, n = 18; loop recorder monitoring, n = 6) were diagnosed. Our predefined AF Risk Score (cutoff ≥4 points; highest Youden's index) had a sensitivity of 92% and a specificity of 67% for 1-year prediction of AF. Notably, only two CS patients with <4 score points were diagnosed with AF later on (negative predictive value 98%). A clinical risk score for 1-year prediction of AF in CS with high sensitivity, reasonable specificity and excellent negative predictive value is presented. Generalizability of our score needs to be tested in external cohorts with continuous cardiac rhythm monitoring.

Sections du résumé

BACKGROUND AND PURPOSE
Atrial fibrillation (AF) often remains undiagnosed in cryptogenic stroke (CS), mostly because of limited availability of cardiac long-term rhythm monitoring. There is an unmet need for a pre-selection of CS patients benefitting from such work-up. A clinical risk score was therefore developed for the prediction of AF after CS and its performance was evaluated over 1 year of follow-up.
METHODS
Our proposed risk score ranges from 0 to 16 points and comprises variables known to be associated with occult AF in CS patients including age, N-terminal pro-brain natriuretic peptide, electrocardiographic and echocardiographic features (supraventricular premature beats, atrial runs, atrial enlargement, left ventricular ejection fraction) and brain imaging markers (multi-territory/prior cortical infarction). All CS patients admitted to our Stroke Unit between March 2018 and August 2019 were prospectively followed for AF detection over 1 year after discharge.
RESULTS
During the 1-year follow-up, 24 (16%) out of 150 CS patients with AF (detected via electrocardiogram controls, n = 18; loop recorder monitoring, n = 6) were diagnosed. Our predefined AF Risk Score (cutoff ≥4 points; highest Youden's index) had a sensitivity of 92% and a specificity of 67% for 1-year prediction of AF. Notably, only two CS patients with <4 score points were diagnosed with AF later on (negative predictive value 98%).
CONCLUSIONS
A clinical risk score for 1-year prediction of AF in CS with high sensitivity, reasonable specificity and excellent negative predictive value is presented. Generalizability of our score needs to be tested in external cohorts with continuous cardiac rhythm monitoring.

Identifiants

pubmed: 34519135
doi: 10.1111/ene.15102
pmc: PMC9292187
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

149-157

Informations de copyright

© 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Références

Neurology. 2016 Jan 19;86(3):261-9
pubmed: 26683642
Eur J Neurol. 2016 Feb;23(2):375-81
pubmed: 26470854
Int J Stroke. 2021 Jan;16(1):29-38
pubmed: 32423317
Ther Adv Neurol Disord. 2019 Apr 11;12:1756286419842698
pubmed: 31007721
Future Cardiol. 2015 May;11(3):323-31
pubmed: 26021638
Int J Cardiol. 2017 Oct 1;244:175-179
pubmed: 28624331
J Stroke Cerebrovasc Dis. 2015 Oct;24(10):2263-9
pubmed: 26190307
J Neurol Sci. 2013 Jan 15;324(1-2):57-61
pubmed: 23102659
Cardiology. 2017;138(3):133-140
pubmed: 28654919
Stroke. 2015 May;46(5):1210-5
pubmed: 25851771
J Cell Mol Med. 2010 Nov;14(11):2552-60
pubmed: 20738444
Stroke. 2009 Aug;40(8):2866-8
pubmed: 19461041
N Engl J Med. 2014 Jun 26;370(26):2467-77
pubmed: 24963566
N Engl J Med. 2018 Jun 07;378(23):2191-2201
pubmed: 29766772
Chest. 2018 Nov;154(5):1121-1201
pubmed: 30144419
Cerebrovasc Dis. 2009;27(5):502-8
pubmed: 19342826
J Stroke Cerebrovasc Dis. 2018 Jan;27(1):203-209
pubmed: 29032886
Int J Med Inform. 2000 Sep;58-59:147-55
pubmed: 10978917
Eur J Neurol. 2022 Jan;29(1):149-157
pubmed: 34519135
N Engl J Med. 2019 May 16;380(20):1906-1917
pubmed: 31091372
Circ Res. 2014 Apr 25;114(9):1453-68
pubmed: 24763464
Eur J Cardiothorac Surg. 2016 Nov;50(5):e1-e88
pubmed: 27663299
Int J Stroke. 2016 Apr;11(3):302-12
pubmed: 26763916
J Neurol. 2009 Jun;256(6):954-63
pubmed: 19252783
J Neurol. 2016 Jan;263(1):150-6
pubmed: 26530513
Circ Heart Fail. 2020 Feb;13(2):e006541
pubmed: 32065760
Neurology. 2019 Jan 8;92(2):e115-e124
pubmed: 30530796
Int J Stroke. 2014 Jun;9(4):419-25
pubmed: 23981586
Lancet Neurol. 2021 Jun;20(6):426-436
pubmed: 34022169
Stroke. 2019 Aug;50(8):2223-2226
pubmed: 31216968

Auteurs

Markus Kneihsl (M)

Department of Neurology, Medical University of Graz, Graz, Austria.

Egbert Bisping (E)

Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Daniel Scherr (D)

Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Harald Mangge (H)

Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.

Simon Fandler-Höfler (S)

Department of Neurology, Medical University of Graz, Graz, Austria.

Isabella Colonna (I)

Department of Neurology, Medical University of Graz, Graz, Austria.

Melanie Haidegger (M)

Department of Neurology, Medical University of Graz, Graz, Austria.

Sebastian Eppinger (S)

Department of Neurology, Medical University of Graz, Graz, Austria.

Edith Hofer (E)

Department of Neurology, Medical University of Graz, Graz, Austria.
Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.

Franz Fazekas (F)

Department of Neurology, Medical University of Graz, Graz, Austria.

Christian Enzinger (C)

Department of Neurology, Medical University of Graz, Graz, Austria.
Division of Neuroradiology, Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Graz, Austria.

Thomas Gattringer (T)

Department of Neurology, Medical University of Graz, Graz, Austria.
Division of Neuroradiology, Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Graz, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH